First experiences withnewtopicalimmunomodulating therapy of atopic dermatitis in 40 children has been analyzed by authors. Parameters of long-term efficacy and safety were evaluated during 1 year double-blind, randomised clinical study following the introduction of 1% pimecrolimus cream into the topical treatment of atopic dermatitis. The novel therapeutic regimen was effective and more safe than current conventional therapy, reducing the incidence of flares of atopic dermatitis in children. The therapy did not influence the skin recal antigen tests. Pimecrolimus-based regimen patients required substantially less corticosteroids than those in control groups.

        Key words: pimecrolimus - atopic dermatitis - topical treatment